Bristol-myers Squibb Compnay

Syngene International Limited

Pratt-whitney Canada Corp

Jun Shi

Peter Tai Wah Cheng

Yan Shi

Shiwei Tao

Hao Zhang

Robert F Kaltenbach, Iii

Jun Li

James R Corte

Lawrence J Kennedy

Ying Wang

Tianan Fang

William R Ewing

Sutjano Jusuf

Steven J Walker

Suresh Dhanusu

Bruce A Ellsworth

Ximao Wu

Ramesh Babu Reddigunta

Andres S Hernandez

Mimi Lifen Quan

Donald J P Pinto

David C Jarmon

Zilun Hu

Chongqing Sun

Yeheng Zhu

Kumaravel Selvakumar

Laura Nielsen

Zhengxiang Gu

Xiang-Yang Ye

David J Donnelly

Elizabeth Anne Jurica

Shaoluo L Butler

Stephen P O'Connor

Zhenqiu Hong

Aleksander Kojovic

Joonyoung Kim

Tritin Tran

Ramesh Badu Reddigunta

Zhu Yeheng

Sun Chongqing

Lev Alexander Prociw

Iii Robert F Kaltenbach

Robert F Kaltenbach Iii

Robert F Iii Kaltenbach

Stephen P O'CONNOR

The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Cyclobutyl carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Oxabicyclo acids as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Cyclopentyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists

Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. 

Cyclohexyl acid triazole azoles as LPA antagonists

Cyclohexyl acid triazole azines as LPA antagonists

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

Diamide macrocycles having factor XIa inhibiting activity

The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

Diamide macrocycles that are FXIa inhibitors

Growing community of inventors

Pennington, NJ, United States of America

Jun Shi